Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone-Reference-Cited by-同舟云学术

Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone

Published:2017-07-01 Issue:7 Volume:3 Page:906
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hortobagyi Gabriel N.¹,Van Poznak Catherine²,Harker W. Graydon³,Gradishar William J.⁴,Chew Helen⁵,Dakhil Shaker R.⁶,Haley Barbara B.⁷,Sauter Nicholas⁸,Mohanlal Ramon⁹,Zheng Ming⁸,Lipton Allan¹⁰

Affiliation:

1. Department of Breast Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston

2. Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor

3. Utah Cancer Specialists, Salt Lake City, Utah

4. Department of Medicine–Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois

5. Department of Internal Medicine–Hematology/Oncology, UC Davis Comprehensive Cancer Center, Sacramento, California

6. Department of Hematology/Oncology, Cancer Center of Kansas, Wichita

7. Department of Hematology/Oncology, University of Texas Southwestern Medical Center, Dallas

8. Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey

9. Consultant, AstraZeneca, London, England10Consultant, BeyondSpring Pharmaceuticals, New York, New York

10. Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 140 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Commiphora myrrha n-hexane extract suppressed breast cancer progression through induction of G0/G1 phase arrest and apoptotic cell death by inhibiting the Cyclin D1/CDK4-Rb signaling pathway;Frontiers in Pharmacology;2024-08-05

2. Bone-modifying agents for bone metastasis in patients with breast cancer;Kosin Medical Journal;2024-06-30

3. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy;Cureus;2024-06-28

4. Approach to Bone Health in the Patient With Breast Cancer;The Journal of Clinical Endocrinology & Metabolism;2024-06-12

5. Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma;Cancer Immunology, Immunotherapy;2024-03-02